Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New drugs for the treatment of Anderson-Fabry disease.

Journal of nephrology - 1 Feb 2021

Feriozzi Sandro, Hughes Derralynn A

Abstract excerpt

Enzyme replacement therapy (ERT) of the Anderson-Fabry disease (AFD) has changed the outcome of patients. However, ERT has some limitations: a restricted volume of distribution, requirement for intravenous access, and stimulation of the production of anti-drug antibodies. Studies of new drugs aiming to improve the clinical effectiveness and convenience of therapy have been reported. Migalastat, a pharmacological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Galactosidase
Share to Enzyme Replacement Therapy
Share to Fabry Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pharmaceutical Preparations

Source

Identifiers

PMID: 32193835
DOI: 10.1007/s40620-020-00721-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New drugs for the treatment of Anderson-Fabry disease.PMID 32193835Read ↗

Developments in the treatment of Fabry disease.Semantic proximity Read ↗

Fabry Disease Therapy: State-of-the-Art and Current ChallengesSemantic proximity Read ↗

A review and recommendations for oral chaperone therapy in adult patients with Fabry disease.Semantic proximity Read ↗

Therapeutic advances in Fabry disease: The future awaits.Semantic proximity Read ↗

FABRY DISEASE: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat. What Do We Know Today?Semantic proximity Read ↗

Current and Investigational Therapeutics for Fabry DiseaseSemantic proximity Read ↗

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.Semantic proximity Read ↗

[Chaperone molecules: The example of Fabry disease].Semantic proximity Read ↗

Challenges in Fabry disease: the combination of two individually amenable GLA variants may be nonamenable to migalastat.Semantic proximity Read ↗

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).Semantic proximity Read ↗

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.Semantic proximity Read ↗

Chaperone Therapy in Fabry Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.